Podcasts about Bergman

Time for Sports Graffiti! Mason and Andy Kamenetzky circle back to the most underrated movies. Bergman drops into the studio for a Boys in Blue Report! Who will be the Dodgers starting second baseman this season? The crew dive a little into the Rams and what they will do this offseason? Who does Mason feel bad for? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Melissa Lavasani & Jay Kopelman join our podcast to discuss how psychedelic policy is actually moving in Washington, DC. Lavasani leads Psychedelic Medicine Coalition, a DC-based advocacy organization focused on educating federal officials and advancing legislation around psychedelic medicine. Kopelman is CEO of Mission Within Foundation, which provides scholarships for veterans and first responders seeking psychedelic-assisted therapy retreats, often outside the United States. The conversation centers on veterans, the VA, and why that system may be the first realistic federal pathway for psychedelic care. Early Themes Lavasani describes PMC's work on Capitol Hill, including hosting events that bring lawmakers, staffers, and advocates into the same room. Her focus is steady engagement. In DC, progress often happens through repeated conversations, not headlines. Kopelman shares his background as a Marine and how his own psychedelic-assisted therapy experience led him to Mission Within. The foundation has funded more than 250 scholarships for veterans and first responders seeking treatment for PTSD, mild traumatic brain injury, depression, and addiction. They connect this work to pending veteran-focused legislation and explain why the VA matters. As a closed health system, the VA can pilot programs, gather data, and refine protocols without the pressures of private healthcare markets. Core Insights A recent Capitol Hill gathering, For Veteran Society, brought together members of Congress and leaders from the psychedelic caucus. Lavasani describes candid feedback from lawmakers. The message was clear: coordinate messaging, avoid fragmentation, and move while bipartisan interest remains. Veteran healthcare is not framed as the final goal. It is a starting point. If psychedelic therapies can demonstrate safety and effectiveness within the VA, broader adoption becomes more plausible. Kopelman raises operational realities that must be addressed: Standardized safety protocols across providers Integration support, not medication alone Clear training pathways for clinicians Real-world data beyond tightly screened clinical trials They also address recent negative headlines involving ibogaine treatment abroad. Kopelman emphasizes the need for shared learning across providers, especially when adverse events occur. Lavasani argues that inconsistency within the ecosystem can slow federal confidence. Later Discussion and Takeaways The discussion widens to federal momentum around addiction and mental health. Lavasani notes that new funding initiatives signal growing openness to innovative treatment models, even if psychedelics are not named explicitly in every announcement. Both guests stress that policy moves slowly by design. Meetings, follow-ups, and relationship building often matter more than public statements. For clinicians, researchers, operators, and advocates, the takeaways are direct: Veterans are likely the first federal pathway Public education remains essential Safety standards must be shared and transparent Integration and workforce development need attention now If psychedelic medicine enters federal systems, infrastructure will determine success. Frequently Asked Questions What do Melissa Lavasani & Jay Kopelman say about VA psychedelic policy? They argue that veteran-focused legislation offers a realistic first federal pathway for psychedelic-assisted care. Is ibogaine currently available through the VA? No. They discuss ibogaine in the context of private retreats and future possibilities, not an existing VA program. Why do Melissa Lavasani & Jay Kopelman emphasize coordination? Lawmakers respond more positively when advocates present aligned messaging and clear priorities. What safety issues are discussed by Melissa Lavasani & Jay Kopelman? They highlight the need for standardized screening, monitoring, integration support, and transparent review of adverse events. Closing Melissa Lavasani & Jay Kopelman provide a grounded look at how psychedelic policy develops inside federal systems. Their message is practical: veterans may be the first lane, but long-term success depends on coordination, safety standards, and sustained engagement. Closing This episode captures a real-time view of how federal policy could shape the next phase of the psychedelic resurgence, especially through veteran-facing legislation and VA infrastructure. Melissa Lavasani & Jay Kopelman argue that coordination, public education, and shared safety standards will shape whether access expands with credibility and care. Transcript Joe Moore: [00:00:00] Hello everybody. Welcome back to Psychedelics Today. Today we have two guests, um, got Melissa Sani from Psychedelic Medicine Coalition. We got Jake Pelman from Mission Within Foundation. We're gonna talk about I bga I became policy on a recent, uh, set of meetings in Washington, DC and, uh, all sorts of other things I'm sure. Joe Moore: But thank you both for joining me. Melissa Lavasani: Thanks for having us. Jay Kopelman: Yeah, it's a pleasure. Thanks. Joe Moore: Yeah. Um, Melissa, I wanna have you, uh, jump in. First. Can you tell us a little bit about, uh, your work and what you do at PMC? Melissa Lavasani: Yeah, so Psychedelic Medicine Coalition is, um, the only DC based Washington DC based advocacy organization dedicated to the advancing the issue of psychedelics, um, and making sure the federal government has the education they need, um, and understands the issue inside out so that they can generate good policy around, around psychedelic medicines. Melissa Lavasani: [00:01:00] Uh, we. Host Hill events. We host other convenings. Our big event every year is the Federal Summit on psychedelic medicine. Um, that's going to be May 14th this year. Um, where we talk about kinda the pressing issues that need to be talked about, uh, with government officials in the room, um, so that we can incrementally move this forward. Melissa Lavasani: Um, our presence here in Washington DC is, is really critical for this issue's success because, um, when we're talking about psychedelic medicines, um, from the federal government pers perspective, you know, they are, they are the ones that are going to initiate the policies that create a healthcare system that can properly facilitate these medicines and make sure, um, patient safety is a priority. Melissa Lavasani: And there's guardrails on this. And, um, you know, there, it's, it's really important that we have. A home base for this issue in Washington DC just [00:02:00] because, uh, this is very complicated as a lot of your viewers probably understand, and, you know, this can get lost in the mix of all the other issues that, um, lawmakers in DC are focused on right now. Melissa Lavasani: And we need to keep that consistent presence here so that this continues to be a priority for members of Congress. Joe Moore: Mm. I love this. And Jay, can you tell us a bit about yourself and mission within Foundation? Jay Kopelman: Yeah, sure. Joe, thanks. Uh, I, I am the CEO of Mission within Foundation. Prior to this, most of my adult life was spent in the military as a Marine. Jay Kopelman: And I came to this. Role after having, uh, a psychedelic assisted therapy experience myself at the mission within down in Mexico, which is where pretty much we all go. Um, we are here to help [00:03:00] provide, uh, access for veterans and first responders to be able to attend psychedelic assisted therapy retreats to treat issues like mild TBI, post-traumatic stress disorder, uh, depression, sometimes addiction at, at a very low level. Jay Kopelman: Um, and, and so we've, we've been doing this for a little more than a year now and have provided 250 plus scholarships to veterans and first responders to be able to access. These retreats and these, these lifesaving medicines. Um, we're also partnered, uh, you may or may not know with Melissa at Psychedelic Medicine Coalition to help advance education and policy, specifically the innovative, uh, therapy Centers of Excellence Act [00:04:00] that Melissa has worked for a number of years on now to bring to both Houses of Congress. Joe Moore: Thank you for that. Um, so let's chat a little bit about what this event was that just, uh, went down, uh, what, what was it two weeks ago at this point? Melissa Lavasani: Yeah. Yeah. It's called For Veteran Society and it's all, um, there's a lot of dialogue on Capitol Hill about veterans healthcare and psychedelics, but where I've been frustrated is that, you know, it was just a lot of. Melissa Lavasani: Talk about what the problems are and not a lot of talk about like how we actually propel things forward. Um, so it, at that event, I thought it was really important and we had three members of Congress there, um, Morgan Latrell, who has been a champion from day one and his time in Congress, um, having gone through the experience himself, um, [00:05:00] at Mission within, um, and then the two chairs of the psychedelic caucus, uh, Lou Correa and Jack Bergman. Melissa Lavasani: And we really got down to the nitty gritty of like w like why this has taken so long and you know, what is actually happening right now? What are the possibilities and what the roadblocks are. And it was, I thought it was a great conversation. Um, we had an interesting kind of dynamic with Latres is like a very passionate about this issue in particular. Melissa Lavasani: Um, I think it was, I think it was really. A great event. And, you know, two days later, Jack Bergman introduced his new bill for the va. Um, so it was kind of like the precursor to that bill getting introduced. And we're just excited for more and more conversations about how the government can gently guide this issue to success. Joe Moore: Hmm. Yeah. [00:06:00] That's fantastic. Um, yeah, I was a little bummed I couldn't make it, but next time, I hope. But I've heard a lot of good things and, um, it's, it sounded like there was some really important messages in, in terms of like feedback from legislators. Yeah. Yeah. Could you speak to that? Melissa Lavasani: Yeah, I mean, I think when, uh, representative Latrell was speaking, he really impressed on us a couple things. Melissa Lavasani: Um, first is that, you know, they really kind of need the advocates to. Coordinate, collaborate and come up with like a, a strategic plan, you know, without public education. Um, talking to members of Congress about this issue is, is really difficult. You know, like PMC is just one organization. We're very little mission within, very little, um, you know, we're all like, kind of new in navigating, um, this not so new issue, but new to Washington DC [00:07:00] issue. Melissa Lavasani: Um, without that public education as a baseline, uh, it's, it's, you have to spend a lot of time educating members of Congress. You know, that's like one of our things is, you know, we have to, we don't wanna tell Congress what direction to go to. We wanna provide them the information so they understand it very intimately and know how to navigate through things. Melissa Lavasani: Um, and secondly. Um, he got pretty frank with us and said, you know, we've got one cha one chance at this issue. And it's like, that's, that's kind of been like my talking point since I started. PMC is like, you have a very limited window, um, when these kind of issues pop up and they're new and they're fresh and you have a lot of the veteran community coming out and talking about it. Melissa Lavasani: And there's a lot of energy there. But now is the time to really move forward, um, with some real legislation that can be impactful. Um, but, you know, we've gotta [00:08:00] be careful. We, we forget, I think sometimes those of us who are in the ecosystem forget that our level of knowledge about these medicines and a lot of us have firsthand experience, um, with these drugs and, and our own healing journeys is, um, we forget that there is a public out there that doesn't have the level of knowledge that we all have. Melissa Lavasani: And, um. We gotta make sure that we're sticking to the right elements of, of, of what needs to happen. We need to be sure that our talking points are on track and we're not getting sideways about anything and going down roads that we don't need to talk about. It's why, um, you know, PMC is very focused on, um, moving forward veteran legislation right now. Melissa Lavasani: Not because we're a veteran organization, but because we're, we see this long-term policy track here. Um, we know where we want to get [00:09:00] to, um. Um, and watching other healthcare issues kind of come up and then go through the VA healthcare system, I think it's a really unique opportunity, um, to utilize the VA as this closed system, the biggest healthcare system in the country to evaluate, uh, how psychedelics operate within systems like that. Melissa Lavasani: And, you know, before they get into, um, other healthcare systems. What do we need to fix? What do we need to pay attention to? What's something that we're paying too much attention to that doesn't necessarily need that much attention? So it's, um, it's a real opportunity to look at psychedelic medicines within a healthcare system and obviously continue to gather the data. Melissa Lavasani: Um, Bergman's Bill emerging, uh, expanding veteran access to emerging treatments. Um, not only mandates the research, it gives the VA authority for this, uh, for running trials and, and creating programs around psychedelic medicines. But also, [00:10:00] one of the great things about it, I think, is it provides an on-ramp for veterans that don't necessarily qualify for clinical trials. Melissa Lavasani: You know, I think that's one of the biggest criticisms of clinical trials is like you're cre you're creating a vacuum for people and people don't live in a vacuum. So we don't necessarily know what psychedelics are gonna look like in real life. Um, but with this expanding veteran access bill that Bergman introduced, it provides the VA an opportunity to provide this access under. Melissa Lavasani: Um, in a, in a safe container with medical supervision while collecting data, um, while ensuring that the veteran that is going through this process has the support systems that it needs. So, um, you know, I think that there's a really unique opportunity here, and like Latrell said, like, we've got one shot at this. Melissa Lavasani: We have people's attention in Congress. Um, now's the time to start acting, and let's be really considerate and thoughtful about what we're doing with it. Joe Moore: Thanks for that, Melissa and Jay, how, [00:11:00] anything to add there on kind of your takeaways from the this, uh, last visit in dc? Jay Kopelman: Yeah, I, I think that Melissa highlighted it really well and there, there were a couple other things that I, I think, you know, you could kind of tie it all together with some other issues that we face in this country, uh, and that. Jay Kopelman: Uh, representative Correa brought up as well, but one of the things I wanted to go back and say is that veterans have kind of led this movement already, right? So, so it's a, it's a good jumping off point, right? That it's something people from both sides of the aisle, from any community in America can get behind. Jay Kopelman: You know, if you think about it, uh, in World War ii, you know, we had a million people serving our population was like, not even 200 million, but now [00:12:00] we have a population of 330 million, and at any given time there might be a million people in uniform, including the Reserve and the National Guard. So it's, it, it's an easy thing to get behind this small part of the population that is willing to sign that contract. Jay Kopelman: Where you are saying, yeah, I'm going to defend my country, possibly at the risk of my l my own life. So that's the first thing. The other thing is that the VA being a closed health system, and they don't have shareholders to answer to, they can take some risks, they can be innovative and be forward thinking in the ways that some other healthcare systems can't. Jay Kopelman: And so they have a perfect opportunity to show that they truly care for their veterans, which don't, I'm not saying they don't, but this would be an [00:13:00] opportunity to show that carrot at a whole different level. Uh, it would allow them to innovate and be a leader in something as, uh, as our friend Jim Hancock will say, you know. Jay Kopelman: When he went to the Naval Academy, they had the world's best shipbuilding program. Why doesn't the VA have the world's best care program for things like TBI and PTSD, which affects, you know, 40 something percent of all veterans, right? So, so there's, there's an opportunity here for the VA to lead from the front. Jay Kopelman: Um, the, these medicines provide, you know, reasonably lasting care where it's kind of a one and done. Whereas with the current systems, the, you know, and, and [00:14:00] again, not to denigrate the VA in any way, they're doing the best job they can with the tools in their toolbox, right? But maybe it's time for a trip to Home Depot. Jay Kopelman: Let's get some new tools. And have some new ways of fixing what's broken, which is really the way of doing things. It's not, veterans aren't broken, we are who we are. Um, but it's a, it's a way to fix what isn't working. So I, I think that, you know, given there's tremendous veteran homelessness still, you know, addiction issues, all these things that do translate to the population at large are things that can be worked on in this one system, the va that can then be shown to have efficacy, have good data, have [00:15:00] good outcomes, and, and take it to the population at large. Joe Moore: Mm-hmm. Brilliant. Thanks for that. And so there was another thing I wanted to pivot to, which is some of the recent press. So we've, um, seen a little bit of press around some, um, in one instance, some bad behavior in Mexico that a FI put out Americans thrive again, put out. And then another case there was a, a recent fatality. Joe Moore: And I think, um, both are tragic. Like we shouldn't be having to deal with this at this point. Um, but there's a lot of things that got us here. Um, it's not necessarily the operator's fault entirely, um, or even at all, honestly, like some medical interventions just carry a lot of risk. Like think, think about like, uh, how risky bypass surgery was in the nineties, right? Joe Moore: Like people were dying a lot from medical interventions and um, you know, this is a major intervention, uh, ibogaine [00:16:00] and also a lot of promise. To help people quite a bit. Um, but as of right now, there's, there's risk. And part of that risk, in my opinion, comes from the inability of organizations to necessarily collaborate. Joe Moore: Like there's no kind of convening body, sitting in the middle, allowing, um, for, and facilitating really good data sharing and learnings. Um, and I don't, I don't necessarily see an organization stepping up and being the, um, the convener for that kind of work. I've heard rumors that something's gonna happen there, and I'm, I'm hopeful I'll always wanna share my opinion on that. Joe Moore: But yeah. I don't know. Jay, from your perspective, is there anything you want to kind of speak to about, uh, these two recent incidents that Americans for Iboga kind of publicized recently? Jay Kopelman: Yeah, so I, I'll echo your sentiment, of course, that these are tragic incidents. Um, and I, [00:17:00] I think that at least in the case of the death at Ambio, AMBIO has done a very good job of talking about it, right? Jay Kopelman: They've been very honest with the information that they have. And like you said, there are risks inherent to these medicines, and it's like anything else in medicine, there are going to be risks. You know, when I went through, uh, when I, when I went through chemo, you know, there were, there are risks. You know, you don't feel well, you get sick. Jay Kopelman: Um, and, and it. There are processes in place to counter that when it happens. And there are processes and, and procedures and safety protocols in place when caring for somebody going through an ibogaine [00:18:00] journey. Uh, when I did it, we had EKG echocardiogram. You're on a heart monitor the entire time they push magnesium via iv. Jay Kopelman: You have to provide a urinalysis sample to make sure that there is nothing in your system that is going to potentially harm you. During the ibogaine, they have, uh, a cardiologist who is monitoring the heart monitors throughout the ibogaine experience. So the, the safety protocols are there. I think it's, I think it's just a matter of. Jay Kopelman: Standardizing them across all, all providers, right? Like, that would be a good thing if people would talk to one another. Um, as, as in any system, right? You've gotta have [00:19:00] some collaboration. You've gotta have standardization, you know, so, you know, they're not called standard operating procedures for nothing. Jay Kopelman: That means that in a, you know, in a given environment, everybody does things the same way. It's true in Navy and Marine Corps, air Force, army Aviation, they have standard operating procedures for every single aircraft. So if you fly, let's say the F 35 now, right? Because it's flown by the Navy, the Marine Corps, and the Air Force. Jay Kopelman: The, the emergency procedures in that airplane are standardized across all three services, so you should have the same, or, you know, with within a couple of different words, the same procedures and processes [00:20:00] across all the providers, right? Like maybe in one document you're gonna change, happy to glad and small dog to puppy, but it's still pretty much the, the same thing. Jay Kopelman: And as a service that provides scholarships to people to go access these medicines and go to these retreats, you know, my criteria is that the, this provider has to be safe. Number one, safety's paramount. It's always gotta be very safe. It should, it has to be effective. And you know, once you have those two things in place, then I have a comfort level saying, okay, yeah, we'll work with this provider. Jay Kopelman: But until those standardized processes are in place, you'll probably see these one-off things. I mean, some providers have been doing this longer than others and have [00:21:00] really figured out, you know, they've, they've cracked the code and, you know, sharing that across the spectrum would be good. Um, but just when these things happen, having a clearing house, right, where everybody can come together and talk about it, you know, like once the facts are known because. Jay Kopelman: To my knowledge, we still don't know all the facts. Like as, you know, as horrible as this is, you still have to talk about like an, has an autopsy been performed? What was found in the patient's system? You know, there, there are things there that we don't know. So we need to, we need to know that before we can start saying, okay, well this is how we can fix that, because we just don't know. Jay Kopelman: And, you know, to their credit, you know, Amio has always been safe to, to the, to the best of my knowledge. You know, I, [00:22:00] I haven't been to Ambio myself, but people that I have worked with have been there. They have observed, they have seen the process. They believe it's safe, and I trust their opinion because they've seen it elsewhere as well. Jay Kopelman: So yeah, having, having that one place where we can all come together when this happens, it, it's almost like it should be mandatory. In the military when there's a training accident, we, you know, we would have to have what's called a safety standout. And you don't do that again for a little while until you figure out, okay, how are we going to mitigate that happening again? Jay Kopelman: Believe me, you can go overboard and we don't want to do that. Like, we don't wanna just stop all care, but maybe stop detox for a week and then come back to it. [00:23:00] Joe Moore: Yeah. A dream would be, let's get like the, I don't know, 10, 20 most popular, uh, or well-known operators together somewhere and just do like a three day debrief. Joe Moore: Hey, everybody, like, here's what we see. Let's work on this together. You know how normal medicine works. And this is, it's hard because this is not necessarily, um, something people feel safe about in America talking about 'cause it's illicit here. Um, I don't understand necessarily how the operations, uh, relate to each other in Mexico, but I think that's something to like the public should dig into. Joe Moore: Like, what, what is this? And I, I'll start digging into that. Um, I, I asked a question recently of somebody like, is there some sort of like back channel signal everybody's using and there's no clear Yes. You know? Um, I think it would be good. That's just a [00:24:00] start, you know, that's like, okay, we can actually kind of say hi and watch out for this to each other. Jay Kopelman: It's not like we don't all know one another, right? Joe Moore: Yes. Jay Kopelman: Like at least three operators we're represented. At the Aspen Ibogaine meeting. So like that could be, and I think there was a panel kind of loosely related to this during Aspen Ibogaine meeting, but Joe Moore: mm-hmm. Jay Kopelman: It, you know, have a breakout where the operators can go sit down and kind of compare notes. Joe Moore: Right. Yeah. Melissa, do you have any, uh, comments on this thread here? And I, I put you on mute if you didn't see that. Um, Melissa Lavasani: all right, I'm off mute. Um, yeah, I think that Jay's hits the nail on the head with the collaboration thing. Um, I think that it's just a [00:25:00] problem across the entire ecosystem, and I think that's just a product of us being relatively new and upcoming field. Melissa Lavasani: Um, uh, it's a product of, you know. Our fundraising community is really small, so organizations feel like they are competing for the same dollars, even though their, their goals are all the same, they have different functions. Um, I think with time, I mean, let's be honest, like if we don't start collaborating and, and the federal government's moving forward, the federal government's gonna coordinate for us. Melissa Lavasani: And not, that might not necessarily be a bad thing, but, you know, we understand this issue to a whole other level that the federal government doesn't, and they're not required to understand it deeply. They just need to know how to really move forward with it the proper way. Um, but I think that it. It's really essential [00:26:00] that we all have this come together moment here so we can avoid things. Melissa Lavasani: Uh, I mean, no one's gonna die from bad advocacy. So like I've, I have a bit of an easier job. Um, but it can a, a absolutely stall efforts, um, to move things forward in Washington DC when, um, one group is saying one thing, another group is saying another thing, like, we're not quite at a point yet where we can have multiple lines of conversation and multiple things moving forward. Melissa Lavasani: Um, you know, for PMC, it's like, just let's get the first thing across the finish line. And we think that is, um, veteran healthcare. And, um, I know there's plenty of other groups out there that, that want the same thing. So, you know, I always, the reason why I put on the Federal Summit last year was I kind of hit my breaking point with a lack of collaboration and I wanted to just bring everyone in the same room and say like, all right, here are the things that we need to talk about. Melissa Lavasani: And I think the goal for this year is, um. To bring people in the same room and say, we talked about [00:27:00] we scratched the surface last year and this is where we need to really put our efforts into. And this is where the opportunities are. Um, I think that is going to, that's going to show the federal government if we can organize ourselves, that they need to take this issue really seriously. Melissa Lavasani: Um, I don't think we've done a great job at that thus far, but I think there's still plenty of time for us to get it together. Um, and I'm hoping with these two, uh, VA bills that are in the house right now and Senate is, is putting together their version of these two bills, um, so that they can move in tandem with each other. Melissa Lavasani: I think that, you know, there's an opportunity here for. Us to show the federal government as an ecosystem, Hey, we, we are so much further ahead and you know, this is what we've organized and here's how we can help you, um, that would make them buy into this issue a bit more and potentially move things forward faster. Melissa Lavasani: Uh, at this point in time, it's, I think that, [00:28:00] you know, psychedelics aren't necessarily the taboo thing that they, they used to be, but there's certainly places that need attention. Um, there's certainly conversations that need to be had, and like I said, like PMC is just one organization that can do this. Um, we can certainly organize and drive forward collaboration, but I, like we alone, cannot cover all this ground and we need the subject matter experts to collaborate with us so we can, you know, once we get in the door, we wanna bring the experts in to talk to these officials about it. Melissa Lavasani: So I. I, I really want listeners to really think about us as a convener of sorts when it comes to federal policy. Um, and you know, I think when, like for example, in the early eighties, a lot of people have made comparisons to the issue of psychedelics to the issue of AIDS research and how you have in a subject matter that's like extremely taboo and a patient population that the government [00:29:00] quite honestly didn't really care about in the early eighties. Melissa Lavasani: But what they did as an ecosystem is really organized themselves, get very clear on what they wanted the federal government to do. And within a matter of a couple years, uh, AIDS research funding was a thing that was happening. And what that, what that did was that ripple effect turned that into basically finding new therapies for something that we thought was a death, death sentence before. Melissa Lavasani: So I think. We just need to look at things in the past that have been really successful, um, and, and try to take the lessons from all of these issues and, and move forward with psychedelics. Joe Moore: Love that. And yes, we always need to be figuring out efficient approaches and where it has been successful in the past is often, um, an opportunity to mimic and, and potentially improve on that. Melissa Lavasani: Yeah. Jay Kopelman: One, one thing I think it's important to add to this part of the conversation is that, [00:30:00] you know, Melissa pointed out there are a number of organizations that are essentially doing the same thing. Jay Kopelman: Um, you know, I like to think we do things a little bit differently at Mission within Foundation in that we don't target any one specific type of service member. We, we work with all veterans. We work with first responders, but. What that leads to is that there are, as far as I've seen, nothing but good intentioned people in this space. Jay Kopelman: You know, people who really care about their patient population, they care about healing, they are trying to do a good job, and more importantly, they're trying to do good. Right? It, it, I think they all see the benefit down the road that this has, [00:31:00] pardon me, not just for veterans, but for society as a whole. Jay Kopelman: And, and ultimately that's where I would like to see this go. You know, I, I would love to see the VA take this. Take up this mantle and, and run with it and provide great data, great outcomes. You know, we are doing some data collection ourselves at Mission within foundation, albeit anecdotal based on surveys given before and after retreats. Jay Kopelman: But we're also working with, uh, Greg Fonzo down at UT Austin on a brain study he's doing that will have 40 patients in it when it's all said and done. And I think we have two more guys to put through that. Uh, and then we'll hit the 40. So there, there's a lot of good here that's being done by some really, really good people who've been doing this for a long time [00:32:00] and want to want nothing more than to, to see this. Jay Kopelman: Come to, come full circle so that we can take care of many, many, many people. Um, you know, like I say, I, I wanna work myself out of a job here. I, I just, I would love to see this happen and then I, you know, I don't have to send guys to Mexico to do this. They can go to their local VA and get the care that they need. Jay Kopelman: Um, but one thing that I don't think we've touched on yet, or regarding that is that the VA isn't designed for that. So it's gonna be a pretty big lift to get the right types of providers into the va with the knowledge, right, with the institutional knowledge of how this should be done, what is safe, what is effective, um, and then it, it's not just providing these medicines to [00:33:00] people and sending them home. Jay Kopelman: You don't just do that, you've gotta have the right therapists on the backend who can provide the integration coaching to the folks who are receiving these medicines. And I'm not just talking, I bga, even with MDMA and psilocybin, you should have a proper period of integration. It helps you to understand how this is going to affect you, what it, what the experience really meant, you know, because it's very difficult sometimes to just interpret it on your own. Jay Kopelman: And so what the experience was and what it meant to you. And, and so it will take some time to spin all that up. But once it's, once it's in place, you know, the sky's the limit. I think. Joe Moore: Kinda curious Jay, about what's, what's going on with Ibogaine at the federal level. Is there anything at VA right now? [00:34:00] Jay Kopelman: At the va? No, not with ibogaine. And, you know, uh, we, we send people specifically for IBOGAINE and five MEO, right? And, and so that, that doesn't preclude my interest in seeing this legislation passed, right? Jay Kopelman: Because it, it will start with something like MDMA or psilocybin, but ultimately it could grow to iboga, right? It the think about the cost savings at, at the va, even with psilocybin, right? Where you could potentially treat somebody with a very inexpensive dose of psilocybin or, or iboga one time, and then you, you don't have to treat them again. Jay Kopelman: Now, if I were, uh, you know, a VA therapist who's not trained in psychedelic trauma therapy. I might be worried [00:35:00] about job security, but it's like with anything, right? Like ultimately it will open pathways for new people to get that training or the existing people to get that training and, and stay on and do that work. Jay Kopelman: Um, which only adds another arrow to their quiver as far as I'm concerned, because this is coming and we're gonna need the people. It's just like ai, right? Like ai, yeah. Some people are gonna lose some jobs initially, and that's unfortunate. But productivity ultimately across all industries will increase and new jobs will be created as a result of that. Jay Kopelman: I mean, I was watching Squawk Box one morning. They were talking about the AI revolution and how there's gonna be a need for 500,000 electricians to. Build these systems that are going to work with the AI [00:36:00] supercomputers and, and so, Joe Moore: mm-hmm. Jay Kopelman: Where, where an opportunity may be lost. I think several more can be gained going forward. Melissa Lavasani: And just to add on what Jay just said there, there's nothing specific going on with Ibogaine at, at the va, but I think this administration is, is taking a real look at addiction in particular. Uh, they just launched, uh, a new initiative, uh, that's really centered on addiction treatments called the Great American Recovery. Melissa Lavasani: And, um, they're dedicating a hundred million dollars towards treating addiction as like a chronic treatable disease and not necessarily a law enforcement issue. So, um, in that initiative there will be federal grant programs for prevention and treatment and recovery. And, um, while this isn't just for psychedelic medicines, uh, I think it's a really great opportunity for the discussion of psychedelics to get elevated to the White House. Melissa Lavasani: Um, [00:37:00] there's also, previous to this announcement last week from the White House, there's been a hundred million dollars that was dedicated at, um, at ARPA h, which is. The advanced research projects, uh, agency for healthcare, um, and that is kind of an agency that's really focused on forward looking, um, treatments and technologies, uh, for, um, a, a whole slew of. Melissa Lavasani: Of issues, but this a hundred million dollars is dedicated to mental health and addiction. So there's a lot of opportunity there as well. So we, while I think, you know, some people are talking about, oh, we need a executive order on Iboga, it's like, well, you know, the, the president is thinking, um, about, you know, what issues can land with his, uh, voting block. Melissa Lavasani: And I think it's, I don't think we necessarily need a specific executive order on Iboga to call this a success. It's like, let's look at what, [00:38:00] um, what's just been announced from the White House. They're, they're all in on. Thinking creatively and finding, uh, new solutions for this. And this is kind of, this aligns with, um, HHS secretaries, uh, Robert F. Melissa Lavasani: Kennedy Junior's goals when he took on this, this role of Health Secretary. Um, addiction has been a discussion that, you know, he has personal, um, a personal tie to from his own experience. And, um, I think when this administration started, there was so much like fervor around the, the dialogue of like, everyone's talking about psychedelics. Melissa Lavasani: It was Secretary Kennedy, it was, uh, secretary Collins at the va. It was FDA Commissioner Marty Macari. And I think that there's like a lot of undue frustration within folks 'cause um, you don't necessarily snap your fingers and change happens in Washington dc This is not the city for that. And it's intentionally designed to move slow so that we can avoid really big mistakes. Melissa Lavasani: Um. [00:39:00] I think we're a year into this administration and these two announcements are, are pretty huge considering, um, you know, the, we, there are known people within domestic policy council that don't, aren't necessarily supportive of psychedelic medicine. So there's a really amazing progress here, and frustrating as it might be to, um, just be waiting for this administration to make some major move. Melissa Lavasani: I think they are making major moves like for Washington, DC These, these are major moves and we just gotta figure out how we can, um, take these initiatives and apply them to the issue of psychedelic medicines. Joe Moore: Thanks, Melissa. Um, yeah, it is, it is interesting like the amount of fervor there was at the beginning. You know, we had, uh. Kind of one of my old lawyers, Matt Zorn, jumped in with the administration. Right. And, um, you know, it was, uh, really cool to [00:40:00] see and hopeful how much energy was going on. It's been a little quiet, kind of feels like a black box a little bit, but I, you know, there was, Melissa Lavasani: that's on me. Melissa Lavasani: Maybe I, we need to be more out in public about like, what's actually happening, because I feel like, like day in and day out, it's just been, you gotta just mm-hmm. Like have that constant beat with the government. Mm-hmm. And, um, it's, it's, it's not the photo ops on the hill, it's the conversations that you have. Melissa Lavasani: It's the dinner parties you go to, it's the fundraisers you attend, you know? Mm-hmm. That's why I, I kind of have to like toot my own horn with PCs. Like, we need to be present here at, at not only on the Hill, not only at the White House, but kind of in the ecosystem of Washington DC itself. There's, it's, there are like power players here. Melissa Lavasani: There are people that are connected that can get things done, like. I mean, the other last week we had a big snow storm. I walked over to my friend's house, um, to have like a little fire sesh with them and our kids, and his next door neighbor came over. He was a member of Congress. I talked about the VA bills, like [00:41:00] we're reaching out to his office now, um, to get them, um, up to speed and hopefully get their co-sponsorship for, uh, the two VA bills. Melissa Lavasani: So, I mean, it, the little conversations you have here are just as important as the big ones with the photo ops. So, um, it, it's, it's really like, you know, building up that momentum and, and finding that time where you can really strike and make something happen. Joe Moore: Mm-hmm. Yeah. Jay, anything to add there? Jay Kopelman: Yeah, I was just gonna say that, you know, I, I, I think the fervor is still there, right? Jay Kopelman: But real life happens. Melissa Lavasani: Yes, Jay Kopelman: yes. And gets in the way, right? So, Melissa Lavasani: yeah, Jay Kopelman: I, I can't imagine how many issues. Secretary Kennedy has every day much less the president. Like there's so many things that they are dealing with on a daily basis, right? It, we, we just have to work to be the squeaky wheel in, in the right way, right. Jay Kopelman: [00:42:00] With the, with the right information at the right time. Like just inundating one of these organizations with noise, it's then it be with Informa, it just becomes noise, right? It it, it doesn't help. So when we have things to say that are meaningful and impactful, we do, and Melissa does an amazing job of that. Jay Kopelman: But, you know, it, it takes time. You know, it's, you know, we're not, this is, this is like turning an aircraft carrier, not a ski boat. Melissa Lavasani: Yeah, Joe Moore: yeah, absolutely. Um, and. It's, it's understandably frustrating, I think for the public and the psychedelic public in particular because we see all this hope, you know, we continue to get frustrated at politics. It's nothing new, right? Um, and we, we wanna see more people get well immediately. [00:43:00] And I, I kind of, Jay from the veteran perspective, I do love the kind of loud voices like, you're making me go to Mexico for this. Joe Moore: I did that and you're making me leave the country for the thing that's gonna fix me. Like, no way. And barely a recognition that this is a valid treatment. You know, like, you know, that is complicated given how medicine is structured here domestically. But it's also, let's face the facts, like the drug war kind of prevented us from being able to do this research in the first place. Joe Moore: You know? Thanks Nixon. And like, how do we actually kind of correct course and say like, we need to spend appropriately on science here so we can heal our own people, including veterans and everybody really. It's a, it's a dire situation out there. Jay Kopelman: Yeah. It, it really is. Um, you know, we were talking briefly about addicts, right? Jay Kopelman: And you know, it's not sexy. People think of addicts as people who are weak-minded, [00:44:00] right? They don't have any self-control. Um, but, but look at, look at the opioid crisis, right? That Brian Hubbard was fighting against in Kentucky for all those years. That that was something that was given to the patient by a doctor that they then became dependent on, and a lot of people died from that. Jay Kopelman: And, and so you, you know, it's, I I don't think it's fair to just put all addicts in a box. Just like it's not fair to put all veterans in a box. Just like it's not fair for doctors, put all their patients in a box. We're individuals. We, we have individual needs. Our, our health is very individual. Like, I, I don't think I should be put in the same box as every other 66-year-old that my doctor sees. Jay Kopelman: It's not fair. [00:45:00] You know, if you, if you took my high school classmates and put us all in a photo, we're all gonna have different needs, right? Like, some look like they're 76, not 66. Some look like they're 56. Not like they're, we, we do things differently. We live our lives differently. And the same is true of addicts. Jay Kopelman: They come to addiction from different places. Not everybody decides they want to just try heroin at a party, and all of a sudden they're addicted. It happens in, in different ways, you know, and the whole fentanyl thing has been so daggum nefarious, right? You know, pushing fentanyl into marijuana. Jay Kopelman: Somebody's smoking a joint and all of a sudden they're addicted to fentanyl or they die. Melissa Lavasani: I think we're having a, Jay Kopelman: it's, it's just not fair to, to say everybody in this pot is the same, or everybody in this one is the same. We have [00:46:00] to look at it differently. Joe Moore: Yeah. I like to zoom one level out and kind of talk about, um, just how hurt we are as a country, as a world really, but as a country specifically, and how many people are out of work for so many. Joe Moore: Difficult reasons and away from their families for so many kind of tragic reasons. And if we can get people back to their families and back to work, a lot of these things start to self-correct, but we have to like have those interventions where we can heal folks and, and get them back. Um, yeah. And you know, everything from trauma, uh, in childhood, you know, adulthood, combat, whatever it is. Joe Moore: Like these things can put people on the sidelines. And Jay, to your point, like you get knee surgery and all of a sudden you're, you know, two years later you're on the hunt for Fentanyl daily. You know, that's tough. It's really tough. Carl Hart does a good job talking about this kind of addiction pipeline and [00:47:00] a few others do as well. Joe Moore: But it's just, you know, kind of putting it in a moral failure bucket. It's not great. I was chatting with somebody about, um, veterans, it's like you come back and you're like, what's gonna make me feel okay right now? And it's not always alcohol. Um, like this is the first thing that made me feel okay, because there's not great treatments and there's, there's a lot of improvements in this kind of like bringing people back from the field that needs to happen. Joe Moore: In my opinion. I, it seems to be shared by a lot of people, but yeah, there's, it's, it's, IGA is gonna be great. It's gonna be really important. I really can't wait for it to be at scale appropriately, but there's a lot of other things we need to fix too, um, so that we can just, you know, not have so many people we need to, you know, spend so much money healing. Joe Moore: Mm-hmm. Jay Kopelman: Yeah. You ahead with that. We don't need the president to sign an executive order to automatically legalize Ibogaine. Right. But it would be nice if he would reschedule it so that [00:48:00] then then researchers could do this research on a larger scale. You know, we could, we could now get some real data that would show the efficacy. Jay Kopelman: And it could be done in a safe environment, you know? And, and so that would be, do Joe Moore: you have any kind of figures, like, like, I've been talking about this for a while, Jay. Like, does it drop the cost a lot of doing research when we deschedule things? Jay Kopelman: I, I would imagine so, because it'll drop the cost of accessing the medicines that are being researched. Jay Kopelman: Right? You, you would have buy-in from more organizations. You know, you might even have a pharma company that comes into this, you know, look at j and j with the ketamine, right? They have, they have a nasal spray version of ketamine that's doing very well. I mean, it's probably their, their biggest revenue [00:49:00] provider for them right now. Jay Kopelman: And, and so. You know, you, it would certainly help and I think, I think it would lower costs of research to have something rescheduled rather than being schedule one. You know it, people are afraid to take chances when you're talking about Schedule one Melissa Lavasani: labs or they just don't have the money to research things that are on Schedule one. Melissa Lavasani: 'cause there's so much in an incredible amount of red tape that you have to go through and, and your facility has to be a certain way and how you contain those, uh, medicines. Oh, researching has to be in a specific container and it's just very cumbersome to research schedule one drugs. So absolutely the cost would go down. Melissa Lavasani: Um, but Joe Moore: yeah, absolutely. Less safes. Melissa Lavasani: Yeah. Joe Moore: Yes. Less uh, Melissa Lavasani: right. Joe Moore: Locked. Yeah. Um, it'll be really interesting when that happens. I'm gonna hold out faith. That we can see some [00:50:00] movement here. Um, because yeah, like why make healing more expensive than it needs to be? I think like that's potentially a protectionist move. Joe Moore: Like, I'm not, I'm not here yet, but, um, look at AbbVie's, uh, acquisition of the Gilgamesh ip. Mm-hmm. Like that's a really interesting move. I think it was $1.2 billion. Mm-hmm. So they're gonna wanna protect that investment. Um, and it's likely going to be an approved medication. Like, I don't, I don't see a world in which it's not an approved medication. Joe Moore: Um, you know, I don't know a timeline, I would say Jay Kopelman: yeah. Joe Moore: Less than six years, just given how much cash they've got. But who knows, like, I haven't followed it too closely. So, and that's an I bga derivative to be clear, everybody, um mm-hmm. If you're not, um, in, in the loop on that, which is hopeful, you know? Joe Moore: Mm-hmm. But I don't know what the efficacy is gonna be with that compared to Ibogaine and then we have to talk about the kind of proprietary molecule stuff. Um, there's like a whole bunch of things that are gonna go on here, and this is one of the reasons why I'm excited about. Federal involvement [00:51:00] because we might actually be able to have some sort of centralized manufacturer, um, or at least the VA could license three or four generic manufacturers per for instance, and that way prices aren't gonna be, you know, eight grand a dose or whatever. Joe Moore: You know, it's, Jay Kopelman: well, I think it's a very exciting time in the space. You know, I, I think that there's the opportunity for innovation. There is the opportunity for collaboration. There's the opportunity for, you know, long-term healing at a very low cost. You know, that we, we have the highest healthcare cost per capita in the world right here in the us. Jay Kopelman: And, and yet we are not the number one health system in the world. So to me, that doesn't add up. So we need to figure out a way to start. Bringing costs down for a lot of people and [00:52:00] at the same time increasing, increasing outcomes. Joe Moore: Absolutely. Yeah. There's a lot of possible outcome improvements here and, and you know, everything from relapse rates, like we hear often about people leaving a clinic and they go and overdose when they get home. Tragically, too common. I think there's everything from, you know, I'm Jay, I'm involved in an organization called the Psychedelics and Pain Association. Joe Moore: We look at chronic pain very seriously, and IGA is something we are really interested in. And if. We could have better, you know, research, there better outcome measures there. Um, you know, perhaps we can have less people on opioids to begin with from chronic pain conditions. Um, Jay Kopelman: yeah, I, I might be due for another Ibogaine journey then, because I deal with chronic pain from Jiujitsu, but, Joe Moore: oh gosh, let's Jay Kopelman: talk Joe Moore: later. Jay Kopelman: That's self inflicted. Some people would say take a month off, but Melissa Lavasani: yeah, Jay Kopelman: I'm [00:53:00] not, I'm not that smart. Joe Moore: Yeah. Um, but you know, this, uh, yeah, this whole thing is gonna be really interesting to see how it plays out. I'm endlessly hopeful pull because I'm still here. Right. I, I've been at this for almost 10 years now, very publicly, and I think we are seeing a lot of movement. Joe Moore: It's not always what we actually wanna see, but it is movement nonetheless. You know, how many people are writing on this now than there were before? Right. You know, we, we have people in New York Times writing somewhat regularly about psychedelics and. Even international media is covering it. What do we have legalization in Australia somewhat recently for psilocybin and MDMA, Czech Republic. Joe Moore: I think Germany made some moves recently. Mm-hmm. Um, really interesting to see how this is gonna just keep shifting. Um Jay Kopelman: mm-hmm. Joe Moore: And I think there's no way that we're not gonna have prescription psychedelics in three years in the United States. It pro probably more like a [00:54:00] year and a half. I don't know. Do you, are you all taking odds? Melissa Lavasani: Yeah. I mean, I think Jay Kopelman: I, I gotta check Cal sheet, see what they're saying. Melissa Lavasani: I think it's safe to say, I mean, this could even come potentially the end of this year, I think, but definitely by the end of 2027, there's gonna be at least one psychedelic that's FDA approved. Joe Moore: Yeah. Yeah. Melissa Lavasani: If you're not counting Ketamine. Joe Moore: Right. Jay Kopelman: I, I mean, I mean it mm-hmm. It, it doesn't make sense that it. Shouldn't be or wouldn't be. Right. The, we've seen the benefits. Mm-hmm. We know what they are. It's at a very low cost, but you have to keep in mind that these things, they need to be done with the right set setting and container. Right. And, and gotta be able to provide that environment. Jay Kopelman: So, but I would, I would love, like I said, I'd love to work myself out of a job here and see this happen, not just for our veterans, [00:55:00] but for everybody. Joe Moore: Mm-hmm. Um, so Melissa, is there a way people can get involved or follow PMC or how can they support your work at PMC? Melissa Lavasani: Yeah, I mean, follow us in social media. Melissa Lavasani: Um, our two biggest platforms are LinkedIn and Instagram. Um, I'm bringing my newsletter back because I'm realizing, um, you know, there is a big gap in, in kind of like the knowledge of Washington DC just in general. What's happening here, and I think, you know, part of PC's value is that we're, we are plugged into conversations that are being had, um, here in the city. Melissa Lavasani: And, you know, we do get a little insight. Um, and I think that that would really quiet a lot of, you know, the, a lot of noise that, um, exists in the, our ecosystem. If, if people just had some clarity on like, what's actually happening or happening here and what are the opportunities and, [00:56:00] um, where do we need more reinforcement? Melissa Lavasani: Um, and, and also, you know, as we're putting together public education campaign, you know. My, like, if I could get everything I wanted like that, that campaign would be this like multi-stakeholder collaborative effort, right? Where we're covering all the ground that we need to cover. We're talking to the patient groups, we're talking to traditional mental health organizations, we're talking to the medical community, we're talking to the general population. Melissa Lavasani: I think that's like another area that we, we just seem to be, um, lacking some effort in. And, you know, ultimately the veteran story's always super compelling. It pulls on your heartstrings. These are our heroes, um, of our country. Like that, that is, that is meaningful. But a lot of the veteran population is small and we need the, like a, the just.[00:57:00] Melissa Lavasani: Basic American living in middle America, um, understanding what psychedelics are so that in, in, in presenting to them the stories that they can relate to, um, because that's how you activate the public and you activate the public and you get them to see what's happening in these clinical trials, what the data's been saying, what the opportunities are with psychedelics, and then they start calling their members of Congress and saying, Hey, there is this. Melissa Lavasani: Bill sitting in Congress and why haven't you signed onto it? And that political pressure, uh, when used the right way can be really powerful. So, um, I think, you know, now we're at this really amazing moment where we have a good amount of congressional offices that are familiar enough with psychedelics that they're willing to move on it. Melissa Lavasani: Um, there's another larger group, uh, that is familiar with psychedelics and will assist and co-sponsor legislation, but there's still so many offices that we haven't been able to get to just 'cause like we don't have all the time in the world and all the manpower in the world to [00:58:00] do it. But, you know, that is one avenue is like the advocates can speak to the, the lawmakers, the experts speak to the lawmakers, and we not, we want the public engaged in this, you know, ultimately, like that's. Melissa Lavasani: Like the best form of harm reduction is having an informed public. So we are not, they're not seeing these media headlines of like, oh, this miracle cure that, um, saved my family. It's like, yes, that can happen psychedelics. I mean, person speaking personally, psychedelics did save my family. But what you miss out of that story is the incredible amount of work I put into myself and put into my mental health to this day to maintain, um, like myself, my, my own agency and like be the parent that I wanna be and be the spouse that I wanna be. Melissa Lavasani: So, um, we, we need to continue to share these stories and we need to continue to collaborate to get this message out because we're all, we're all in the same boat right now. We all want the same things. We want patients to have safe and [00:59:00] affordable access to psychedelic assisted care. Um, and, uh. We're just in the beginning here, so, um, sign up for our newsletter and we can sign up on our website and then follow us on social media. Melissa Lavasani: And, um, I anticipate more and more events, um, happening with PMC and hopefully we can scale up some of these events to be much more public facing, um, as this issue grows. So, um, I'm really excited about the future and I'm, I've been enjoying this partnership with Mission Within. Jay is such a professional and, and it really shows up when he needs to show up and, um, I look forward to more of that in the future. Joe Moore: Fantastic. And Jay, how can people follow along and support mission within Foundation? Jay Kopelman: Yeah, again, social media is gonna be a good way to do that. So we, we are also pretty heavily engaged on LinkedIn and on Instagram. Um, I do [01:00:00] share, uh, a bit of my own stuff as well. On social media. So we have social media pages for Mission within Foundation, and we have a LinkedIn page for mission within foundation. Jay Kopelman: I have my own profiles on both of those as well where people can follow along. Um, one of the other things you know that would probably help get more attention for this is if the general public was more aware of the numbers of professional athletes who are also now pursuing. I began specifically to help treat their traumatic brain injuries and the chronic traumatic encephalopathy that they've, uh, suffered as a result of their time in professional sports or even college sports. Jay Kopelman: And, you know. I people worship these athletes, and I [01:01:00] think that if more of them, like Robert Gall, were more outspoken about these treatments and the healing properties that they've provided them, that it would get even more attention. Um, I think though what Melissa said, you know, I don't wanna parrot anything she just said because she said it perfectly Right. Jay Kopelman: And I'd just be speaking to hear myself talk. Um, but being collaborative the way that we are with PMC and with Melissa is I think, the way to move the needle on this overall. And like she said, if she could get more groups involved in, in these discussions, it would, it would do wonders for us. Joe Moore: Well, thank you both so much for your hard work out there. I always appreciate it when people are showing up and doing this important, [01:02:00] sometimes boring and tedious, but nevertheless sometimes, sometimes exciting work. And um, so yeah, just thank you both and thank you both for showing up here to psychedelics today to join us and I hope we can continue to support you all in the future. Jay Kopelman: Thank you, Joe. Thank you, Joe. It's a pleasure being with you today and with Melissa, of course, always Melissa Lavasani: appreciate the time and space. Joe Moore: Thanks.  

For pet owners, a diagnosis such as cancer or chronic disease often brings difficult decisions and limited treatment options, many of which involve invasive procedures. While human medicine has advanced significantly, many of these innovations have been slower to reach veterinary care, underscoring the need for more effective and less invasive approaches to animal health. In this episode of Curing with Sound, we speak with Philip Bergman, DVM, MS, PhD, DACVIM-Oncology, Veterinary Program Director at the Focused Ultrasound Foundation. Dr. Bergman oversees Foundation-funded preclinical research and the clinical studies that enroll companion animals, helping to accelerate translational progress across species.  The conversation explores emerging applications of focused ultrasound in veterinary medicine, including its potential role in treating osteosarcoma, glioblastoma, feline diabetes, and other complex conditions. Dr. Bergman also discusses the collaborative One Medicine approach and how it is advancing care for both animals and people.  Discussion highlights: One Medicine Revolution: Companion animals naturally develop many of the same diseases as humans, allowing veterinary research to inform human medicine—and vice versa—through a shared, translational approach. Breakthroughs in Standard of Care: He shares his vision for a “bench-to-bedside-to-kennel” cycle, in which insights from animal clinical trials accelerate human therapies and human breakthroughs inspire new, noninvasive treatment options for pets. The Future of Veterinary Technology: Hear about efforts to develop cost-effective, veterinary-specific focused ultrasound systems designed to bring this technology into everyday clinical practice. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

In this episode of Rewatching Oscar, a classic masterpiece is discussed. Yes, Casablanca has stood the test of time. From the great quotes, the amazing performances, the memorable characters, the love story, and even the wonderful emotional song, As Time Goes By, we remember it all. Looking back, was it deserving of the Best Picture Oscar for 1943? Listen and find out what film critic Jack Ferdman thinks, and which film he chooses for his Rewatch Oscar of that year.This is one special film ... so sit back and take it all in. Jack knows what he's talking about.  Download, listen, and share ALL Rewatching Oscar episodes.SUBSCRIBE and FOLLOW Rewatching Oscar:Website: https://rewatchingoscar.buzzsprout.comApple Podcasts/iTunesSpotifyGoogle PodcastsiHeart RadioPodchaserPodcast AddictTuneInAlexaAmazon Overcasts Podcast Addict Player FMRSS Feed: https://feeds.buzzsprout.com/1815964.rssWebsite: https://rewatchingoscar.buzzsprout.comSocial Media Links: Facebook, Twitter, LinkedIn, Instagram, BlueSkyShare your thoughts and suggestions with us through:Facebook Messenger or email us atjack@rewatchingoscar.com or jackferdman@gmail.comMusic by TurpacShow Producer: Jack FerdmanPodcast Logo Design: Jack FerdmanMovie (audio) trailer courtesy of MovieClips Classic TrailersMovie (audio) clips courtesy of YouTubeSupport us by downloading, sharing, and giving us a 5-star Rating.  It helps our podcast continue to reach many people and make it available to share more episodes with everyone.Send a text

Time for Sports Graffiti! Mason and Ireland discuss the most improbable sports outcomes. Bergman drops into the studio for a ‘Boys in Blue' report! The Dodgers have re-signed Bullpen arm Evan Phillips! Take a listen to Tom Brady and Logan Paul debating athleticism. Can you bet on anything these days? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Las parejas enamoradas de Mai Zetterling no lo están, se casan por conveniencia, se abandonan, o se aborrecen. La fijación de la directora con la maternidad, el embarazo, la ansiedad y la angustia, o su desprecio del matrimonio como institución debió confundir bastante al personal. Con una narración audaz, a través de saltos en el tiempo y una cantidad de personajes que en una primera visión del film puede confundir, abrumar al espectador. Zetterling adaptó junto a su pareja en ese momento, David Hughes, el ciclo de novelas de la escritora Agnes von Krusenstjerna. La primera parte del film presenta a las tres mujeres protagonistas. Las tres embarazadas en un hospital, a punto de dar a luz, recuerdan sus vidas, un médico cínico, una tía, Petra, la narradora original en la serie de novelas, o un pintor homosexual, personajes bisagra ambos. En la segunda parte, el solsticio de verano reunirá al grupo entero, ahí entran aún más personajes. Domina la señora Landborg, anfitriona promiscua, locuaz, y cínica a más no poder, sus comentarios no tienen desperdicio. Según ella traer un hijo al mundo es procrear otro idiota, y también suelta en otra ocasión que el fin del matrimonio es hacer que la gente se odie. El cine de Zetterling muestra nexos en común con Ingmar Bergman. El acercamiento de la directora es muy natural y ambicioso, Bergman acota más su mirada a sus obsesiones particulares, la existencia y la muerte , el silencio de Dios, el pecado. Zetterling tuvo la suerte de contar con el operador habitual de Bergman, Sven Nykvist. Su trabajo excepcional nos encierra en la clínica, nos transmite la náusea de la paciente, el miedo de la niña escondida bajo la mesa, o en el otro extremo, el goce de vivir, las jóvenes corriendo desnudas por el campo. La osadía de mostrar deseos lésbicos en el año 1964, el primer plano frontal de los rostros de la alumna y la tutora nos traen a la memoria “Persona”, su perturbadora elucubración sobre la locura y la soledad. Esta noche queremos ser felices de una forma melancólica, igual que Petra, la que ya no quiere ser joven… Chari Medina, Zacarías Cotán, Salvador Limón y Raúl Gallego.

Comedy and radio legend Phil Proctor talks about the origin of the Firesign Theater, his love of radio, his many careers as an actor, reporter, writer, comedian, author, and how he made the New York, San Francisco, and LA scenes when there were scenes to make!  He also talks about his biography “Where's My Fortune Cookie” and how he almost died three times.  Let's see if he survives our podcast. Bio: Proctor is a founding member of the thrice-Grammy-nominated Firesign Theatre, one of Rolling Stone's “Thirty Greatest Acts of All Time” and whose archives were purchased by the Library of Congress. He's appeared on-and-off Broadway, toured the USSR with the Yale Russian Chorus and the US and Canada with Proctor & Bergman and the L.A. Guitar Quartet in Don Quixote. He has appeared in scores of commercials, audiobooks, video games, films and TV shows, receiving Theatre World, LA Weekly, LA Free Press and Drama Critics' awards, and the Norman Corwin Excellence in Audio trophy as well as a recent Emmy for the PBS-aired documentary Feast Your Ears: The Story of WHFS Radio. His voice credits include memorable characters in Academy Award-winning films for Pixar and Disney from A Bug's Life to Inside Out, the Drunken French Monkey in Dr. Dolittle, Dr. Vidic in Assassin's Creed, Simon Stagg in Batman: Arkham Knight, and Howard in the multi-Emmy-winning Rugrats, including a star on the Hollywood Walk of Fame. He has also added scores of voices to the Golden Age of Pulp Fiction series and appeared on Irish radio and live on stage with his late wife, Melinda Peterson, at the 77th Science Fiction Convention in Dublin. He was the announcer for 3 seasons of Big Brother and has a recurring role as Detective Polehaus on the long-running Adventures in Odyssey and can be seen in many old--time radio recreations at the Online Radio Theatre on YouTube. He is a 15-year member of the Antaeus Theater and to accompany his autobiography and audiobook, Where's My Fortune Cookie? co-authored by Brad Schreiber, he co-wrote What to Say to Your Crazy Right-Wing Uncle, with Samuel Joseph and God Help Us! a political comedy which toured the U.S. and Canada starring the late Ed Asner. He currently co-hosts Phil & Ted's Sexy Boomer Show, every Tuesday afternoon on KPFK with Ted Bonnitt, featuring conversations with friends like John Goodman, Penn Jillette, Weird Al,  Laraine Newman and Harry Shearer among others. Learn more about your ad choices. Visit megaphone.fm/adchoices

durée : 01:28:49 - Alan et Marylin Bergman, les paroliers de Barbra Streisand et Michel Legrand - par : Laurent Valière - Quatre Emmy Awards, trois Oscars et deux Grammy Awards : Alan et Marylin Bergman ont écrit les paroles de chansons devenues des standards, de "When you Believe in Spring" à "The Way We Were" et travaillé avec les plus grands de Frank Sinatra à Barbra Streisand. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

On this episode Matt and Jon remember Catherine O'Hara (1954-2026), then discuss Send Help, If I Had Legs, I'd Kick You, F1, The Muppet Show, The Pitt, A Knight of the Seven Kingdoms, Wonder Man and Shrinking, while Jon read Project Hail Mary & the DC/AEW crossover, Magic & Colossus and played Clair Obsur: Expedition 33 while Matt's Bergman and Six Feet Under marathons and he finished Ghost of Yotei. Threads: https://www.threads.net/@jonwahizzle Facebook: https://www.facebook.com/groups/damnthattelevision/ Instagram: https://www.instagram.com/damntvpod Bluesky: https://bsky.app/profile/mattlovestv.bsky.social https://bsky.app/profile/jonwahizzle.bsky.social Letterboxd: https://letterboxd.com/mattlovestv/ https://letterboxd.com/jonwahizzle/ Jon on AIPT: https://aiptcomics.com/author/jonathanw/ Matt's show The Drop: A Pop Culture Mix Tape: wscafm.org Sundays 6-8 PM: https://www.facebook.com/groups/thedropwsca/

« J'essaye toujours de me mettre à côté des fenêtres; pour commencer, j'ai besoin de cette forme de rêve éveillé. » Née en Roumanie, Marta Bergman déménage enfant avec ses parents en Belgique. Elle y étudie la communication et le journalisme, avant d'obtenir son diplôme en réalisation à l'INSAS. Elle début sa carrière en réalisant de nombreux documentaires, s'intéressant tout particulièrement aux communautés Rom de Roumanie. Ses films l'emmènent dans de prestigieux festivals, Visions du Réel, Dok Leipzig, avant que son premier long métrage de fiction, « Seule à mon mariage », ne l'entraine jusqu'à Cannes, où elle présente le film à l'ACID. Son deuxième long métrage de fiction, « L'Enfant bélier », vient de sortir dans les salles belges. Elle s'y penche sur un sujet d'une actualité brûlante, l'accueil que nous faisons des migrant, et les politiques déshumanisantes qui mènent à des drames à répétition. Avec Marta Bergman, on a parlé d'écrire dans des cafés, des périodes d'errance qui précèdent l'écriture tout en en faisant partie, de son désir qui remonte à l'enfance de raconter des histoires, et de sa joie à les partager, de sa manière de faire, intuitive, hors méthode, de la difficulté d'écrire, et de la magie aussi. Le temps d'un coup de fil à l'ancienne, sans video, sans caméra, elle revient pour les Rituels, un podcast créé pour We Love Cinema, sur la place que l'écriture prend dans sa vie et dans son quotidien.

We start the show off with some super cross talk with Mason, Ireland, & O'Shea Jackson Jr. We are live from Rock & Brews in El Segundo. Morales is there for a Live Imaging Thursday, Bergman, and of course D'Marco, Travis and Producer Laura. The Lakers made a trade! The Lakers acquired Luke Kennard from the Atlanta Hawks for Gabe Vincent and 2032 second round pick. How does this move help out the Lakers? What are the Clippers doing? They already traded James Harden and Ivica Zubac. Are they in rebuild mode? Learn more about your ad choices. Visit podcastchoices.com/adchoices

It's been more than half a century since the publication of Silent Spring by the scientist and creative writer Rachel Carson. The seminal volume caught the attention of U.S. presidents, artists and musicians, spurring the environmental movement and leading to the eventual ban of the toxic pesticide DDT. Joining the Mongabay Newscast is environmental writer and director of the creative writing program at Middlebury College, Megan Mayhew Bergman. She unpacks the impact of Carson's work, which came under public attack from chemical companies seeking to discredit her, and how, eventually, the truth broke through. "We don't change our minds usually based on data. We change our minds based on emotion, but historically, it's been pretty taboo for scientists to include emotion in the way that they write. And I feel like Carson risked that here in a way that was really powerful." Please take a minute to let us know what you think of our podcast, here. Image: Megan Mayhew Bergman. Image by Cameron Russell. Environmental writing and authors mentioned in this conversation: Braiding Sweetgrass by Robin Wall Kimmerer Florida by Lauren Groff The Home Place by J. Drew Lanham Hope Is the Thing With Feathers by Christopher Cokinos How Strange a Season by Megan Mayhew Bergman Silent Spring by Rachel Carson Under a White Sky by Elizabeth Kolbert Vesper Flights by Helen Macdonald The Wild Flag by E.B. White Zora Neale Hurston Other works and authors mentioned: Ecology of a Cracker Childhood by Janisse Ray Men We Reaped by Jasmyn Ward A Small Place by Jamaica Kincaid Speak Memory by Vladimir Nabokov —- Timestamps (00:00) Changing hearts and minds (02:46) Rachel Carson's journey to Silent Spring (08:22) Controversy and impact (14:40) Room for a new voice (20:55) Bioaccumulation and what it means (24:07) "We don't change our minds based on data" (26:43) Recommended reads (35:21) The American South and environmental writing (39:57) Lessons for writers

Barry Bergman has been a key music industry figure over a long career including management, publishing, and advocacy. He played a key role in launching the careers of AC/DC, Meat Loaf and John Paul Young. He's published over 400 songs that were recorded by artists like Cher, Michael Bolton, KISS and Joan Jett. Recently he was the Music Supervisor for the Documentary “Queen Mimi” by Yaniv Rokah. And he was a founding member of the Music Managers Forum U.S. and the musicFirst Coalition. My featured song is “Hollywood” from the album The PGS Experience. Spotify link.—-----------------------------------------------------------The Follow Your Dream Podcast:Top 1% of all podcasts with Listeners in 200 countries!Click here for All Episodes Click here for Guest List Click here for Guest Groupings Click here for Guest TestimonialsClick here to Subscribe Click here to receive our Email UpdatesClick here to Rate and Review the podcast—----------------------------------------CONNECT WITH BARRY:www.barrybergman.com—----------------------------------------ROBERT'S LATEST RELEASE:“MA PETITE FLEUR STRING QUARTET” is Robert's latest release. It transforms his jazz ballad into a lush classical string quartet piece. Praised by a host of classical music stars.CLICK HERE FOR YOUTUBE LINKCLICK HERE FOR ALL LINKS—---------------------------------------ROBERT'S RECENT SINGLE“MI CACHIMBER” is Robert's recent single. It's Robert's tribute to his father who played the trumpet and loved Latin music.. Featuring world class guest artists Benny Benack III and Dave Smith on flugelhornCLICK HERE FOR YOUTUBE LINKCLICK HERE FOR ALL LINKS—--------------------------------------ROBERT'S LATEST ALBUM:“WHAT'S UP!” is Robert's latest compilation album. Featuring 10 of his recent singles including all the ones listed below. Instrumentals and vocals. Jazz, Rock, Pop and Fusion. “My best work so far. (Robert)”CLICK HERE FOR THE OFFICIAL VIDEOCLICK HERE FOR ALL LINKS—----------------------------------------Audio production:Jimmy RavenscroftKymera Films Connect with the Follow Your Dream Podcast:Website - www.followyourdreampodcast.comEmail Robert - robert@followyourdreampodcast.com Follow Robert's band, Project Grand Slam, and his music:Website - www.projectgrandslam.comYouTubeSpotify MusicApple MusicEmail - pgs@projectgrandslam.com  

Podcast Guest Professor Paul Bergman easily expresses a kind of joy and delight he has enjoyed in his over 40 years as a Professor at the UCLA School of Law. As retired and now with the status of Emeritus, he continues to allow his students at the Law School to contemplate their upcoming profession in a special light. Listen and you will hear from a pioneering educator who chartered new directions in how to teach law with great creativity. He added also a most crucial element; a determination to have his students see the practice of law as helping people at a most difficult time in their life. Bergman insists that his students understand their role as advocates for their clients so that theymay have a better life. In general his contribution to the UCLA School of Law, which was transformative, was the idea of developing clinical education where real cases are used as teaching tools, dissected and analyzed, with role playing. An evolution from this idea came his next innovation based on his enthusiasm for films to present famous courtroom scenes in movies in his classes. Bergman discovered that using these movie scenes had a certain power in preparing future Lawyers for courtroom experiences. Today, Professor Paul Bergman is as active as ever, continuing to teach a class at the Law School, writing books and bringing his creative approach to classes he teaches in the community. He is the Author of 15 books including THE COURTROOM GOES TO THE MOVIES.

Time for Sports Graffiti! Mason and Andy Kamenetzky dive into the article claiming the Rams did Cooper Kupp ‘dirty.' The crew is joined by Bergman for the ‘Boys in Blue' report. Are there signs that this could be LeBron's last yeast in the NBA? What did Cam Newton have to say about Notre Dame? Learn more about your ad choices. Visit podcastchoices.com/adchoices

A grande richiesta di nessuno tornano le puntate-monstre: qui sfioriamo le due ore, per parlare di quattro uscite piuttosto importanti.Arriva anche nei nostri cinema Marty Supreme, primo progetto solista di Josh Safdie che consacra Chalamet come uno dei migliori della sua generazione.Parliamo poi del nuovo celebrato film di Joachim Trier, Sentimental Value, una storia di famiglia tra Ibsen e Bergman.A stretto giro dal precedente esce al cinema 28 anni dopo - Il tempio delle ossa, il nuovo capitolo della saga di infetti (zombie) targata Alex Garland e Danny Boyle, che qui cede la regia a Nia DaCosta.Chiudiamo con l'ultimo film di Paolo Sorrentino, La Grazia, dove il regista immagina un presidente della Repubblica nelle ultime settimane di mandato, diviso a metà tra impegni istituzionali e questioni familiari irrisolte.Timestamp dei film in scaletta:[01:10] Marty Supreme[40:15] Sentimental Value[58:00] 28 anni dopo - Il tempio delle ossa[1:13:00] La GraziaPer supportarci: ⁠⁠⁠ko-fi.com/incompetentipodcast⁠⁠⁠Per contatti: gliincompetenti@gmail.comincompetentipodcast.it

Detta avsnitt består till största del av en genomgång av samtliga 36 bolag som finns kvar i våra sju B&H-portföljer. Innan detta lite hänt sedan sist (8:30). Bolagen: AQ Group (46:00); Bahnhof (50:13); BTS (53:35); Fenix Outdoor (56:20); Nederman (60:27); Proact IT (63:15); Systemair (66:45); Enea (70:00); Nilörn (73:50); Ogunsen (78:55); Formpipe (82:45); Know IT (85:40); Careium (92:15); VBG (96:36); Björn Borg (100:30); Fagerhult (104:28); Inwido (106:55); Kabe (109:18); New Wave (112:20); Note (115:20); Svedbergs (117:40); Ework (122:20); Scanfil (127:10); Softronic (129:37); Beijer Alma (134:27); Bergman&Beving (135:41); Betsson (137:45); Brdr AOJ (140:24); Byggmax (143:30); Elanders (145:07); G5 (148:25); Harvia (151:37); Thule (153:53); Bravida (157:08); Kitron (160:34); Tomra (163:20). Mycket nöje!Kavaljer hittar ni på: www.kavaljer.seHoldings finns på: https://www.modularfinance.se/holdingsBörsdata finns på: www.Borsdata.sewww.MFN.se har stenkoll på bolagens kommunikation och viktiga datumLäs mer om Läkare utan gränsers verksamhet här: https://lakareutangranser.se/Nästa avsnitt släpps torsdagen den 26 februari. Hosted on Acast. See acast.com/privacy for more information.

In the final episode of Homeroom, Claire Bergman talks about her work supporting families in our District who are experiencing homelessness.

(Aniversario de la Muerte de José Ferrer) José Vicente Ferrer de Otero y Cintrón nació en Santurce, Puerto Rico, el 8 de enero de 1912. A los seis años se trasladó con su padre a la ciudad de Nueva York. De ahí que en 1934 obtuviera su Licenciatura en Humanidades de la Universidad de Princeton, donde se apasionó por el arte dramático, y que posteriormente estudiara literatura francesa en la Universidad de Columbia. En 1943, su interpretación de Yago en la obra «Otelo» lo lanzó a la fama en el mundo artístico. En 1947, cuando se otorgaron por primera vez los premios Tony, recibió el primero de cinco premios Tony de teatro por interpretar por primera vez el personaje Cyrano de Bergerac. Un año más tarde obtuvo la primera de tres nominaciones al Óscar por su actuación como el Delfín en la película «Juana de Arco» protagonizada por Íngrid Bergman. En 1950, José Ferrer recibió la prestigiosa estatuilla por la versión fílmica de «Cyrano de Bergerac», llegando a ser el primer actor en ganar un Óscar por la recreación de un papel teatral en una película. Ese codiciado Óscar lo donó al Teatro de la Universidad de Puerto Rico para que les sirviera de estímulo a los futuros aspirantes a carreras teatrales. Su tercera y última nominación la logró en 1952 por su actuación en la versión original de la película «Moulin Rouge». Entre las obras teatrales que hizo, se destaca «El hombre de la Mancha», en la que encarnó al célebre Don Quijote. Ese mismo año, la Organización de Estados Americanos le rindió homenaje por ser vínculo de excelencia entre la cultura latina y la anglosajona. En total, Ferrer actuó en setenta películas y dirigió trece producciones de Broadway y siete películas. Entre los muchos reconocimientos que recibió durante su carrera como actor, director, escritor, productor, cantante y compositor, se destacan su propia estrella en el Paseo de Estrellas de Hollywood, la primera Medalla Nacional de Arte en 1985 (que le otorgó el ex presidente Ronald Reagan), y su selección en 1981 al Paseo de la Fama del Teatro. Con sobrada razón se le dedicó, en 1990, el Festival de Teatro Latinoamericano. En lo personal, José Ferrer se casó cuatro veces y tuvo seis hijos, uno de ellos el también actor Miguel Ferrer. Quienes no saben que José Ferrer fue tío del actor George Clooney y suegro de la cantante Debby Boone, tal vez tampoco sepan que hablaba cinco idiomas —español, inglés, francés, italiano y alemán— y que los dominaba a tal grado que durante una conferencia de prensa se dirigió a todos los periodistas en sus respectivos idiomas.1 «Un autor puede escribir algo que perdure trescientos años después de su muerte —observó José Ferrer durante una entrevista en 1986—, pero cinco minutos después de mi muerte, ya no puedo actuar ni dirigir más.»2 Quiera Dios que esas palabras, que pronunció el reconocido actor unos seis años antes de su muerte el 26 de enero de 1992, nos lleven a reflexionar que, antes de afrontar nuestra propia muerte, debemos pedirle a Dios que desempeñe el papel de Director de la obra sin igual que es nuestra vida, en la que nosotros somos los actores principales. Porque una vez que muramos, ya será demasiado tarde. Y lo cierto es que cinco minutos después de nuestra muerte, Dios, que es el Guionista que inspiró la Biblia, que ha perdurado miles de años, será el único capacitado para dirigir nuestra actuación eterna. Carlos ReyUn Mensaje a la Concienciawww.conciencia.net 1 Clarissa Santiago Toro, «José Ferrer», Biografías, Fundación Nacional para la Cultura Popular En línea 27 noviembre 2007; Constance Clark, En línea 28 julio 2008; «José Ferrer: Perfil», Puerto Rico Herald, 14 julio 1999 En línea 27 noviembre 2007; Wikipedia, s.v. «José Ferrer» En línea 14 noviembre 2007. 2 «José Ferrer: Perfil», Puerto Rico Herald.

Dejar el alcohol no es cuestión de fuerza de voluntad.Si lo fuera, nadie recaería. La mayoría de personas que intentan dejar de beber fallan por la misma razón: mantienen el mismo entorno, los mismos hábitos y la misma vida… esperando un resultado distinto.En este vídeo te explico 3 duras verdades que casi nadie te dice y que marcan la diferencia entre aguantar unas semanas… o dejar el alcohol para siempre.No hablamos de hígado ni de calorías.Hablamos de psicología, hábitos, identidad y entorno.Porque el alcohol no es solo una bebida: es una función en tu vida. Y si no sustituyes esa función, volverá.Aprenderás:• Por qué cambiar de amistades y contexto puede ser necesario• Por qué quitar el alcohol sin sustituirlo casi nunca funciona• Cómo crear nuevas aficiones que te ayuden a no recaer• Por qué la fuerza de voluntad no es la solución• Cómo hacer un cambio real y sostenible a largo plazoSi estás intentando dejar de beber, o simplemente quieres recuperar el control sobre tus hábitos, este vídeo puede ahorrarte años de frustración.

CINEMA! E ANCORA CINEMA!Nuovo appuntamento con la mia rubrica "improvvisata" in cui esprimo opinioni su film visti da pochi minuti al Cinema per ricordarvi che il CINEMA è AL CINEMA!Torna Joachim Trier con il suo cinema sofferente, diretto eppure non troppo esplicito.Guardando al solito imprescindibile Bergman, Trier ci racconta con "Sentimental Value" la storia di una famiglia unita dall'arte ma con un passato impossibile da dimenticare e un futuro non pianificabile. In parole povere, la vita.

Time for Sports Graffiti! Mason, Ireland, and Pepe dive into today's Oscars nominations! What are the top social media sites of  the year? Bergman joins the guys in the studio for the ‘Boys in Blue' report! What can the MLB do to avoid a lockout before the 2027 season? The crew takes a listen to a Seahawks fan talking about the Rams. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mason and Andy Kamenetzky dive straight into the news of the Los Angeles Dodgers adding Free Agent Kyle Tucker to their already stacked lineup! Bergman drops into the studio to talk about the Kyle Tucker signing. David Kaplan from ESPN Chicago joins the show! The guys talk with Kaplan about the Tucker signing and the Rams taking on the Bears! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Fimm skip taka þátt í rannsóknarleiðangri Hafrannsóknastofnunar í næstu viku. Í honum á að kanna stöðu loðnustofnsins sem heldur til fyrir norðan landið þessa dagana. Niðurstöður verða nýttar til að veita ráðgjöf um hve mikla loðnu verður heimilt að veiða í ár. Loðnan er verðmætur fiskur og ríkir spenna fyrir niðurstöðunum. Elsa María Guðlaugs Drífudóttir talar við Guðmund J. Óskarsson sviðsstjóra hjá Hafró um leiðangurinn og loðnuna sjálfa, sem er nokkuð frábrugðin öðrum fisktegundum sem við Íslendingar veiðum. New European Bauhaus er verkefni á vegum Evrópusambandsins þar sem markmiðið er að gera búsetuumhverfi borga og bæja sjálfbærara, fallegra og aðgengilegra. Hér á Íslandi eru byggingar og verkefni sem eru sagðar í anda New European Bauhaus, og sumir vonast jafnvel til þess að verkefnið geti lagað þau vandamál sem við erum að glíma við hér á Íslandi. En hvað er New European Bauhaus? Í dag fáum við til okkar tvo gesti frá félagssamtökunum Grænni byggð – sem taka þátt í verkefni sem tengist New European Bauhaus á Norðurslóðum – til að ræða þetta nánar. Það eru þær Katarzyna Jagodzinska framkvæmdastjóri og Elín Þórólfsdóttir stjórnarformaður Grænni byggðar. Tónlist: Bergman, Natalie - Shine Your Light On Me. Moses Hightower - Búum til börn. Parton, Dolly - These old bones. Girl in Red - Hemingway

Time for Sports Graffiti! Mason and Ireland are joined by Bergman for a ‘Boys in Blue' Report! Are the Dodgers still in play for the ‘big' free agent names? The crew is joined by Special Guest, Max Kellerman! Will College Football be moving to a 16 team playoff? Learn more about your ad choices. Visit podcastchoices.com/adchoices

When it comes to urgent care profitability, getting patients in the door is only half the battle. Getting paid is the part no one likes to talk about, but it is where many clinics quietly bleed revenue.In this episode of Walk-Ins, Nick and Michael sit down with Guy Bergman and Ed Sherlock from Inbox Health, a platform built to modernize patient billing and remove friction from one of urgent care's biggest pain points. With decades of combined experience across urgent care, health IT, and revenue cycle management, Guy and Ed break down why patient payments now account for as much as 20 to 30 percent of urgent care revenue and why most clinics are leaving a large chunk of that money on the table.The conversation dives into what really causes billing breakdowns, how front desk pressure and poor communication fuel one-star reviews, and why relying solely on an EMR to collect patient balances is no longer enough. From digital-first billing and self-service payment plans to AI-powered billing support and real-time analytics, this episode is a masterclass on how urgent cares can shorten collection timelines, cut call volume, and improve patient satisfaction without adding more stress to already overworked teams.

Artisten Amanda Bergman är aktuell med nya albumet Embraced for a Second as We Die en platta som både blickar inåt och utåt på existentiella plan. Lyssna på alla avsnitt i Sveriges Radios app.

Time for Sports Graffiti! Ireland and Andy Kamenetzky dive into a story and debate if it is funny and a joke or unacceptable and mean. Bergman drops into the studio for the “Boys in Blue Report.” Who are the big MLB free agents that still have not signed? What unwritten rule in basketball does John think makes zero sense? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Kap reveals his personal, biased list of Top 10 teams and Sedano gives commentary with an accompaniment of golden nuggets in the last regular season edition of The Kap 10! One of our MC's, Koby Walsh, is a close friend of The Landman, and he explains what happened when he asked Berg to put him on the air. It stirs up quite a controversy. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Discover invaluable insights and practical strategies to empower leaders in driving successful strategic initiatives. As a seasoned executive or emerging leader, this episode offers essential guidance to elevate your leadership capabilities In this Episode: LindaAnn Rogers, Tom Bradshaw, Nic Krueger, Dr. Matthew Lampe, Lee Crowson, Alexander Abney-King, Peter Plumeau   Visit us https://www.seboc.com/ Follow us on LinkedIn: https://bit.ly/sebocLI Join an open-mic event: https://www.seboc.com/events   References Alagaraja, M., Rose, K., Shuck, B., & Bergman, M. (2015). Unpacking organizational alignment: the view from theory and practice. Journal of Organizational Learning and Leadership 13(1): 18-31.   Mazzetti G. & Schaufeli W.B. (2022). The impact of engaging leadership on employee engagement and team effectiveness: A longitudinal, multi-level study on the mediating role of personal- and team resources. PLoS ONE 17(6): e0269433. https://doi.org/10.1371/journal.pone.0269433   Mgbemena, I., Onyali, C., Ojukwu, H. (2024). Strategic alignment and organizational responsiveness: A process-orientated perspective. International Journal of Academic Management Science Research 8(3).   Pasion-Caiani, S. (2015) Examination of employee alignment as a predictor of work engagement. Master's Theses. DOI: https://doi.org/10.31979/etd.ydep-ks65. https://scholarworks.sjsu.edu/etd_theses/4554

VEM: Stefan SaukYRKE: SkådespelareAVSNITT: 713OM: Fysiken och åldrandet, skolan i Nairobi, filmklimatet i Sverige, Ingmar Bergman som höll sig på avstånd, karate, vari Sauks aktörsmässiga begåvning ligger, Ernst-Hugos plantskola, föräldrarnas skilsmässa, ensamma barndomen, det egna partiprogrammet, ilskan i Stockholmstrafiken, känslorna gentemot Alex & Sigge efter Mardrömsgästen, osvensk uppriktighet, konfliktryktet, känslan av att vara missförstådd och givetvis en hel del om idoga rättelser (fem, närmare bestämt) av K Triumfs eventuellt osanna, långlivade och märkligt konsekventa uppfattning om att Stefan Sauk skulle vara tio år äldre än vad han är.SAMTALSLEDARE: Kristoffer TriumfPRODUCENT: Mattias ÅsénKONTAKT: varvet@triumf.se och Instagram Hosted on Acast. See acast.com/privacy for more information.

Time for Sports Graffiti! Andy Kamenetzky and Su'a Cravens are joined by Bergman in the studio as the guys further discuss the Raiders problems. What do the Raiders do with the number one pick? Is the USC vs Notre Dame game over for good? Su'a and AK are USC alums and weigh in on the topic. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 115 - Happy 2026! The first episode of the new year is our last Bergman discussion. This week we watch and discussed The Seventh Seal (1957) Arguably Bergman's most well-known film, the Seventh Seal follows a knight, his squire, a rag tag group of performers and others during the time of the black plague in Sweden. Those of you familiar with the film Bill and Ted's Bogus Journey might recognize the plot device of death playing a game for the life of the main character. Who borrowed from who? Tune in to find out. And tune in soon as we release our end of the year MRAC film club awards, where we reflect on the year past and all the films we watched.email us at mracfilmclub@gmail.com

Episode 114 - It is week 3 of Ignmar Bergman month here on MRAC, and for this week we watched and discussed To Joy (1950), a film that follows an orchestral musician couple through their turbulent relationship. It's a bit of a gut punch, so grab some tums and strap yourself in. QQ could not join us for this one but we got to meet Caifu, the newest member of the family. Tune in this week, and stay tuned for our final Bergman episode when we will be watching and discussing The Seventh Seal (1957). Pete will also be revealing next month's theme.And stay tuned soon after that for our end of the year MRAC awards ceremony.Email us at mracfilmclub@gmail.com

Ireland is back in the studio on Christmas Eve! Ireland is joined by Bergman to tip off the show, with Ramona Shelburne joining later! The crew dive into the Lakers loss last night vs the Suns. Take a listen to what JJ Redick had to say after the game. Ireland weighs in on the USC vs Notre Dame game situation. Take a listen to former Trojan Keyshawn Johnson talk about the rivalry! Boys in Blue report! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Complete our 2025 survey: ⁠⁠⁠https://unpacked.bio/uihsurvey⁠⁠⁠ Help us take Unpacked podcasts further by supporting our crowdfunding campaign: ⁠⁠⁠https://unpacked.bio/podgift2025 How do you get people who don't talk to talk? In this special live Unpacking Israeli History, Noam Weissman sits down with Pulitzer Prize–winning journalist and Israeli intelligence expert Ronen Bergman (author of Rise and Kill First) for a smart, funny, and deeply human look at the Mossad, Shin Bet, and Israel's security establishment. Recorded in front of a packed audience at Sinai Temple in Los Angeles, Bergman explains how he persuaded hundreds of operatives to open up, why secrecy and ego can be dangerous, and why he believes Israel's real “secret weapon” is democracy and accountability. Then, the discussion turns to the hardest question of all—how October 7 happened—through the lens of misread signals, misallocated attention, and hubris. It's a conversation that's messy, meaningful, and genuinely accessible. Ronen Bermgan writes for the New York Times and Yedioth Ahronoth. He is the author of Rise and Kill First The Secret History of Israel's Targeted Assassinations To sponsor an episode or to be in touch, please email noam@unpacked.media. Check out this episode on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube.⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠This podcast was brought to you by Unpacked, an OpenDor Media brand. ------------------- For other podcasts from Unpacked, check out: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jewish History Nerds⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Soulful Jewish Living⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Stars of David with Elon Gold ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wondering Jews⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Congressman Jack Bergman, representing Michigan's 1st Congressional District, weighs in on escalating actions against Venezuela's regime, which President Trump has labeled a foreign terrorist organization. Bergman discusses the U.S. seizure of a Venezuelan “ghost ship,” strikes against drug-running boats, and the ongoing fight to stop fentanyl and other deadly narcotics from reaching American communities. He pushes back on criticism from the left, noting that U.S. interdiction of drug vessels is nothing new, pointing out that legislation authorizing these actions dates back decades, including measures authored by Democrats like Chuck Schumer. The conversation also turns to issues impacting everyday Americans, including healthcare challenges and gas prices, and why strong leadership matters both at home and abroad.

Time for Sports Graffiti! Mason, Andy Kamenetzky, and Pepe Mantilla take a look at some of Timothee Chalamet's comments about striving for greatness. Why did Edwin Diaz choose the Dodgers over the Mets? Bergman joins the guys in the studio for some news on the Boys in Blue! The Rams have a huge matchup tomorrow vs the Seahawks! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason and Ireland dive into the news of Australia banning social media for kids under the age of 16. Would the Dodgers still dominate in a world with a salary cap? Have you ever been catfished? Take a listen to Justin Herbert postgame after the Chargers win on Monday Night victory. Bergman drops into the studio! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mason and Ireland tip off the show with the Lakers dropping the NBA Cup Quarter Finals last night to the Spurs. Are the Thunder so good that it can make the game boring? How did Lebron respond to comments about not being a contender? Who would you cast for the show regarding Ippei Mizuhara and Ohtani? Bergman drops into the studio for some updates on the Boys in Blue! What is the real news on Skubal to the Dodgers? Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 112 - Pack your bags because we are headed to 1940's-50's Sweden to cover the early films of Ignmar Bergman. Bergman is considered one of the most important directors in the history of cinema so clearly we are not qualified to comment, but we are doing it anyway. You will get our initial reactions to Bergman through the first film he wrote and directed; Prison (1949), as well as some supplemental talk about Thirst (1949). Both films comment on marriage, faith and human nature... which we in turn comment on.Join us for the... fun?and join us next week as we watch an discuss Wild Strawberries (1957) and Summer Interlude (1951)email us at mracfilmclub@gmail.com

Javier Ocaña hoy ha hablado de Toys'R'us y Bergman en la misma sección, de Rambo y Preston Sturges, de "Oso vicioso" y "Los viajes de Sullivan" . Nos ha ocupado la crítica de la nueva película de Noah Baumbach, "Jay Kelly", protagonizada por George Clooney, que continua la misma senda que abrió Bergman con "Fresas salvajes". Por petición popular Ocaña ha visto "Sueños de trenes" y le ha resultado una sucesión de postalitas bonitas para instagram sin nada que contar. Con mucho entusiasmo recomienda "Roofman: un ladrón en el tejado", una historia real delirante muy bien llevada al cine. Y la autocrítica es para "Los viajes de Sullivan" una de las mejores comedias de la historia. 

Mason and Ireland are joined by Morales for Live Imaging Tuesday! The Winter Meetings are here for the MLB! The Dodgers reportedly signed Edwin Diaz to strengthen their bullpen! Bergman drops into the studio to discuss the Dodgers recent addition! Take a listen to the New York Media react to Edwin Diaz coming to LA. Clinton Yates joins the show live from MLB's Winter Meetings! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Ireland and Ramona Shelburne take a listen to Erin Andrews talking about working in Sports Media. Do Ireland and Momo agree with Erin? Bergman joins the show to discuss the Dodgers offseason! Head Coach of the Los Angeles Rams, Sean McVay joins the show! How do the Rams bounce back this week? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason, Ireland, Morales, Mychal Thompson, and Pepe Mantilla are all in the studio together! The guys are joined by President of the Los Angeles Kings Luc Robitaille! Dr. Klapper then joins the show for another Klapper Vision! Bergman drops into the studio to discuss the boys and blue and UCLA vs USC. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Time for Sports Graffiti! Mason and Ramona Shelburne are joined by Bergman for an offseason Boys in Blue report! How many more MVP Awards will Ohtani win in his career? What did Paul Finebaum have to say about Lincoln Riley? What is the current state of USC Football? Who is the right coach for Penn State? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mason and Ireland kick off the show with USC taking on Northwestern tonight! The Lakers are in Atlanta to take on the Hawks tomorrow! How impressed are the guys with the Lakers hot start? The Rams have announced a new kicker! What does the future look like for Austin Reaves? Bergman drops into the studio and discusses the start of the Dodgers offseason! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

In today's Sunday brunch edition, join John Solomon as he welcomes a lineup of insightful guests discussing critical issues from Obamacare subsidies to home title theft. Congressman Jack Bergman, a former Marine general, reveals shocking truths about insurance subsidies that could leave you outraged. Congressman Ralph Norman breaks down the Republican agenda and what may come next after the government reopens. Andy Roth, chairman of the State Freedom Caucus, shares the transformative influence of these groups in Congress. Finally, journalist John Sommer discusses the alarming trend of home title theft and how to safeguard your property.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Mason is joined by Bergman to start the show today! The guys discuss the Dodgers dropping game five. The Blue Jays now lead the World Series, 3 games to 2. Do the Dodgers need a lineup shakeup in game six? Ramona Shelburne joins Mason in the studio for the rest of the show! The crew is joined by Matthew Berry, for ‘Fantasy This or That!' Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Mason is joined by Andy Kamenetzky today in the studio! Morales is here for ‘Live Imaging Tuesday!' The guys dive straight into the Dodgers huge victory last night in 18 innings! The Dodgers take a 2-1 series lead. How special was Ohtani and Will Klein last night? Is Ohtani the best athlete on the planet? Will Kershaw ever be on the mound again at Dodger Stadium? Bergman joins the guys in the studio to discuss the Dodgers wild night! Ice Breakers! Learn more about your ad choices. Visit podcastchoices.com/adchoices